miR Scientific Is Transforming Cancer Management Into What It Should Be

miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform is powered by the miR Sentinel® Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from urinary exosomes.

The miR Leadership Team

Sam Salman

Co-Founder, Chairman & CEO

Martin Tenniswood, Ph.D

Co-Founder and Chief Scientific Officer

Erik Johnson

Chief Operating Officer

Laurence Klotz, MD, FRCSC, CM

Chief Medical Officer

Tal Kimmel

Chief Strategy Officer

Jill Anderson, JD

Chief Legal Officer

Scot Nelson

SVP, Global Head of Commercial

Lesley E. Northrop, PhD, FACMG

SVP, Head of Product Innovation

Advisors

Sebastiano Cossia Castiglioni

Arun Kant

Deepak A. Kapoor, MD

Jim Roosevelt, JD

Alejandro Weinstein

Henry Weinstein

Work At miR

Join a passionate, talented group of scientists, physicians, and business leaders to drive historic change in healthcare

miR Careers

miR Scientific is a majority-owned operating subsidiary of Impact NRS, headquartered in New York with operating subsidiaries in Canada and Israel.

Impact NRS is a leading innovation company developing transformative solutions to address persistent global challenges in human health, sustainable food production and agriculture. Their model incorporates breakthrough advances in science, statistics and computation to develop products and services for early and scalable adoption. Impact NRS collaborates with stakeholders worldwide to enable rapid commercialization of their ESG socially responsible initiatives.